Guselkumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Guselkumab
Monoclonal antibody
Type ?
Target IL23
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6402H9864N1676O1994S42
Molar mass 143.6 kg/mol

Guselkumab is a monoclonal antibody.[1] By targeting the IL-23 subunit alpha (p19 subunit)[2] (which is not part of IL-12) guselkumab was designed to block interleukin-23 but not IL-12. Guselkumab was developed by Janssen Global Services, LLC.

See also[edit]

  • Ustekinumab, a monoclonal antibody targeting both IL-12 and IL-23 and used to treat plaque psoriasis, launched in the United States under the brand name Stelara
  • Tildrakizumab, another experimental, IL-23-specific monoclonal antibody

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Guselkumab, American Medical Association.
  2. ^ Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA (Jan 2001). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity. 13 (5): 715–25. PMID 11114383. doi:10.1016/S1074-7613(00)00070-4.